Le Ma | Pharmacology | Best Researcher Award

Posted on by sciencefather

Dr. Le Ma | Pharmacology | Best Researcher Award

Patents and Future Innovations:

  • With three patents under process, his work bridges research and practical innovation, indicating a strong focus on translational science.

Author Profile

SCOPUS ID

Mr. Pei Yang |Shanghai Mental Health Center | China

 🎓EARLY ACADEMIC PURSUITS:

  • Le Ma pursued his medical doctorate at the School of Pharmacy, Shanghai Jiao Tong University. During his studies, he focused on fundamental and clinical research in neuropsychopharmacology, laying a solid foundation for his future contributions to the field of pain management and pharmacology.

 🏥 Professional Milestones:

  • After earning his doctorate, Le Ma joined the Shanghai Mental Health Center at Shanghai Jiao Tong University School of Medicine in July 2022. His work there included groundbreaking research on pain mechanisms, highlighted by his role as a corresponding author in significant publications. His efforts were recognized by Wiley China Open Science, earning him the title of High-Contribution Author.

🧬 Research Contributions:

  • Le Ma’s primary research revolves around pain and pharmacology, with a particular emphasis on:
    1. The role of store-operated calcium channels in pain progression.
    2. Mechanisms of analgesic drug efficacy, particularly those derived from Chinese herbal medicines.
    3. Development of biomarkers for pain assessment, including glycolytic metabolites and mitochondrial homeostasis.

🌍 IMPACT AND INFLUENCE

  • Le Ma’s work has had a profound impact on pain management, with 16 published papers in high-impact journals such as FEBS Open Bio and Phytomedicine. His innovative studies have advanced our understanding of pain biomarkers and therapeutic targets, influencing clinical approaches to pain treatment globally.

📊 ACADEMIC CITATIONS

  • Le Ma’s research contributions have garnered 106 citations, reflecting the academic community’s recognition of his impactful work in neuropsychopharmacology.

🏅 AWARDS AND RECOGNITIONS

  • Le Ma’s exceptional contributions to neuropsychopharmacology have been acknowledged through 12 prestigious academic awards. His expertise and innovative research have also earned him invitations to participate in 12 academic exchanges, both domestically and internationally, showcasing his leadership and influence in the scientific community.

🧬 MEMBERSHIPS AND AFFILIATIONS

  • As a committed member of the Shanghai Pharmaceutical Association, Le Ma actively contributes to advancing the field of pharmacology. His engagement with this professional body underscores his dedication to fostering collaboration and innovation within the pharmaceutical sciences.

🚀 FUTURE ASPIRATIONS

  • Le Ma envisions bridging the gap between fundamental research and clinical applications by focusing on pain biomarker development and personalized pain management therapies. His future work aims to revolutionize pain assessment and treatment, improving patient outcomes and advancing the field of pharmacology.

🌟 LEGACY AND FUTURE CONTRIBUTIONS

  • Le Ma is poised to further his research through ongoing projects, such as:
    • Investigating mitochondrial homeostasis in astilbin-mediated analgesia.
    • Exploring the succinate-tricarboxylic acid cycle axis as a biomarker for pain.

    With three patents under process and an editorial appointment at the Journal of Neuroimmune Pharmacology, his legacy promises to include both theoretical advancements and practical innovations in pharmacology.

📄Publications

  • Andrographolide exhibits antinociceptive effects in neuropathic rats via inhibiting class Ⅱ MHC associated response and regulating synaptic plasticity
    Authors: Ma, L.; Sun, Y.; Liu, B.; … Chen, J.; Ju, P.
    Journal: Phytomedicine, 2024, 132, 155823
  • Astilbin exerts anti-hypersensitivity by regulating metabolic demand and neuronal activity in rodent model of neuropathic pain
    Authors: Wang, Q.; Duan, D.; Luo, C.; … Yang, S.; Ma, L.
    Journal: Annals of Medicine, 2024, 56(1), 2396561
  • Analysis of Ionomic Profiles of Spinal Cords in a Rat Model with Bone Cancer Pain
    Authors: Huang, J.; Chen, J.; Ma, L.; … Li, X.; Guo, C.
    Journal: Journal of Pain Research, 2024, 17, pp. 1531–1545
  • Alpha 2-adrenoceptor participates in anti-hyperalgesia by regulating metabolic demand
    Authors: Zhang, K.; Ren, Y.-Q.; Xue, Y.; … Guan, J.-Q.; Ma, L.
    Journal: Frontiers in Pharmacology, 2024, 15, 1359319
  • Metformin Alleviates Pain States by Regulating the Balance of Spinal Synaptic Transmission
    Authors: Duan, D.; Wu, X.; Ali, U.; … Mao, Y.; Ma, Y.
    Journal: Journal of Integrative Neuroscience, 2024, 23(1), 2301006

Xuan Zhang | Pharmacology | Best Researcher Award

Posted on by sciencefather

Prof Dr . Xuan Zhang | Pharmacology | Best Researcher Award

Patent Contributions:
  • Dr. Zhang has contributed to various patent filings, showcasing his practical contributions to drug development and medical devices. His patents, especially in areas like anti-pulmonary fibrosis drugs and innovative drug transport simulation devices, highlight his forward-thinking approach and leadership in pharmaceutical innovation
  Prof Dr. Xuan Zhang , Kunming Medical University , China

Profile

Scopus

OrcID

🎓Early Academic Pursuits

  • Xuan Zhang’s academic journey began with a Bachelor of Medicine in Clinical Medicine from Changzhi Medical University in July 2003. he further honed his expertise by obtaining a Master of Medicine in Pharmacology from Kunming Medical University in July 2006. His pursuit of knowledge continued with a Ph.D. in Cell Biology from the University of Chinese Academy of Sciences in January 2013. These academic milestones provided her with a solid foundation in pharmacology and cell biology, setting the stage for his future contributions to anti-inflammatory and immunopharmacological research.

💼Professional Endeavors

  • Dr. Xuan Zhang has had an impressive professional trajectory. he began his research career as a Research Assistant at the Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University from August 2009 to July 2013. His commitment and excellence led to her appointment as an Associate Professor at the same institution, where he worked from August 2013 to September 2021. During this time, he expanded her academic horizons as a Visiting Scholar at the University of Nebraska Medical Center from January to July 2018. In October 2021, she achieved the rank of Professor at the School of Pharmaceutical Sciences & Yunnan Key Laboratory of Pharmacology for Natural Products.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS

  • Dr. Xuan Zhang’s research primarily focuses on anti-inflammatory and immunopharmacology and respiratory pharmacology. His work centers on understanding the pathogenesis and drug development for organ inflammation and fibrosis, with a special emphasis on lung-related conditions. Throughout her career, he has contributed significantly to uncovering molecular mechanisms, particularly in the context of pulmonary fibrosis and acute lung injury. His research projects, funded by prestigious organizations such as the National Natural Science Foundation of China and the Yunnan Provincial Department of Science and Technology, showcase her expertise and her leadership in exploring pharmacological interventions.

🏅ACADEMIC CITES 

  • Dr. Zhang’s academic contributions are extensively cited in the fields of pharmacology and respiratory medicine. His research has garnered attention from scholars worldwide, establishing his as a leading figure in the study of organ fibrosis. His work is continuously referenced in top journals, furthering the understanding of cell signaling pathways and inflammation management.

🏆IMPACT AND INFLUENCE

  • Dr. Zhang has completed a number of important research projects that have advanced the understanding of acute lung injury and pulmonary fibrosis, notably involving compounds like Palmatin and Gentiopicroside. These projects have yielded practical insights into therapeutic approaches, especially concerning key signaling pathways such as MAPK and NF-κB in lung injury. Moreover, his collaborative work with industry has had tangible impacts on pharmaceutical development, particularly in his consultancy projects evaluating vaccine effectiveness and the safety of novel compounds.

🧬PROFESSIONAL MEMBERSHIPS

  • Dr. Zhang is an active member of several prominent organizations, including the Chinese Pharmacological Society and the Yunnan Pharmacological Society. His roles as Deputy Secretary-General and Standing Member of these societies underline her leadership and dedication to advancing pharmacology both in China and internationally.

🔮LEGACY AND FUTURE CONTRIBUTIONS

  • Dr. Zhang’s patents, particularly in the domain of anti-pulmonary fibrosis drugs and innovative drug transport simulation devices, signify her commitment to translating research into practical applications. His continued involvement in groundbreaking research on iridoid glycosides and Geniposide is expected to yield new therapies for pulmonary fibrosis. His current projects, funded by the National Natural Science Foundation and Kunming Medical University, promise to cement his legacy as a pioneer in the field. he is also recognized as a young and middle-aged academic and technical leader in Yunnan Province, ensuring that his influence will extend to future generations of researchers.

📰PUBLICATIONS

  •  Geniposide Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Mice by Inhibiting TGF-β/Smad and p38MAPK Signaling Pathways
    Authors: Yin, J.-B., Wang, Y.-X., Fan, S.-S., Zou, C., Zhang, X.
    Journal: PLoS ONE, 2024, 19(9), e0309833.
  • Mechanism of Xiyanping Injection in Treatment of Acute Lung Injury Using Network Pharmacology and Molecular Docking Analysis
    Authors: Nie, S.-Y., Fan, S.-S., Zhu, Y.-S., Wang, Y.-X., Zhang, X.
    Journal: Chinese Pharmacological Bulletin, 2024, 40(6), pp. 1165–1171.
  • Adult Pancreatoblastoma with Atypical Histological Morphology Combined with Familial Adenomatous Polyposis: A Rare Case Report
    Authors: Wang, Y.-X., Fan, S.-S., Peng, X.-R., Zhu, Y.-S., Zhang, X.
    Journal: Frontiers in Oncology, 2024, 14, 1346964.
  • Case Report: Clinicopathological Analysis of Minute Pulmonary Meningothelial-Like Nodules: Report of 7 Cases
    Authors: Wang, Y.-X., Lei, Z., Yang, M., Zhang, X., Pan, G.-Q.
    Journal: Frontiers in Oncology, 2022, 12, 942517.
  •  New 4,5-seco-20(10→5)-abeo-Abietane Diterpenoids with Anti-Inflammatory Activity from Isodon lophanthoides var. graciliflorus (Benth.) H.Hara
    Authors: Chen, W.-F., Wong, L.-L., Zhang, X., Tang, L.-P., Li, X.
    Journal: Chemistry and Biodiversity, 2019, 16(6), e1900206.